Clinical Trials
27 trialsA Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech, Inc.
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
IVY
Eli Lilly and Company
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
CRIMI
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Swiss Cancer Institute
NivoPlus
Western Regional Medical Center
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
M.D. Anderson Cancer Center
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
Alliance for Clinical Trials in Oncology
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Alliance for Clinical Trials in Oncology
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Eisai Inc.
Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
University of Michigan Rogel Cancer Center
Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Barbara Ann Karmanos Cancer Institute
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
University of Chicago
S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
SWOG Cancer Research Network
Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma
Central European Cooperative Oncology Group
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
Kidney Cancer Research Bureau
Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
Kidney Cancer Research Bureau
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
Stanford University
SOGUG-02-06
Spanish Oncology Genito-Urinary Group